StreetInsider.com News Articles

Form 4 Kailera Therapeutics, For: Jun 09 Filed by: Renaud Ronald C JR

Thu, 11 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260611/26635593.html

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Fri, 05 Jun 2026 19:32:00 -0400

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively
Phase 1 single ascending dose trial, the first

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Fri, 05 Jun 2026 19:32:00 -0400

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively
Phase 1 single ascending dose trial, the first

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Fri, 05 Jun 2026 19:32:00 -0400

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively
Phase 1 single ascending dose trial, the first

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Fri, 05 Jun 2026 19:32:00 -0400

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively
Phase 1 single ascending dose trial, the first

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Fri, 05 Jun 2026 19:32:00 -0400

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively
Phase 1 single ascending dose trial, the first

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Fri, 05 Jun 2026 19:32:00 -0400

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively
Phase 1 single ascending dose trial, the first

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.

A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.

About Kailera Therapeutics

Kailera Therapeutics

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.

A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.

About Kailera Therapeutics

Kailera Therapeutics

Form 10-Q Kailera Therapeutics, For: Mar 31

Tue, 26 May 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260526/26550519.html

Form 8-K Kailera Therapeutics, For: May 26

Tue, 26 May 2026 16:19:00 -0400
si-local-file:///var/storage/secattach/20260526/26550299.html

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Tue, 26 May 2026 16:02:00 -0400

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline
Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program
Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729)
Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE)

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Tue, 26 May 2026 16:02:00 -0400

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline
Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program
Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729)
Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE)

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Wed, 13 May 2026 07:30:00 -0400

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Wed, 13 May 2026 07:30:00 -0400

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Wed, 13 May 2026 07:30:00 -0400

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Wed, 13 May 2026 07:30:00 -0400

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Wed, 13 May 2026 07:30:00 -0400

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Wed, 13 May 2026 07:30:00 -0400

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for

Evercore ISI Starts Kailera Therapeutics (KLRA) at Outperform

Tue, 12 May 2026 06:32:28 -0400

Evercore ISI analyst Umer Raffat initiates coverage on Kailera Therapeutics (NASDAQ: KLRA) with a Outperform rating.
For an analyst ratings summary and ratings history on Kailera Therapeutics click here. For more ratings news on Kailera Therapeutics click here.
Shares of Kailera Therapeutics closed at $22.93 yesterday.

Leerink Partners Starts Kailera Therapeutics (KLRA) at Outperform

Tue, 12 May 2026 06:07:57 -0400

Leerink Partners analyst David R initiates coverage on Kailera Therapeutics (NASDAQ: KLRA) with a Outperform rating and a price target of $36.00.

For an analyst ratings summary and ratings history on Kailera Therapeutics click here. For more ratings news on Kailera Therapeutics click here.

Shares of Kailera Therapeutics closed at $22.93 yesterday.

MBX Biosciences (MBX) PT Raised to $86 at Citizens on 'Good' MBX 4291 Update

Tue, 12 May 2026 05:37:52 -0400

Citizens analyst Jonathan Wolleben raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $86.00 (from $76.00) while maintaining a Market Outperform rating.
The analyst commented, "With the caveats of preliminary, blinded, early, and small data, the MBX 4291 update looks good. We are confident that the PK profile supports monthly dosing, which is a meaningful development. Additionally, the GLP/GIP agonist, which was designed for similar potency as tirzepatide, looks effective, with up to 16% weight loss after just eight weeks. And importantly, the gradual accumulation of drug supports a ‘self-titrating’ dosing paradigm, which translated into a GI tolerability profile

MBX Biosciences (MBX) PT Raised to $86 at Citizens on 'Good' MBX 4291 Update

Tue, 12 May 2026 05:37:52 -0400

Citizens analyst Jonathan Wolleben raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $86.00 (from $76.00) while maintaining a Market Outperform rating.
The analyst commented, "With the caveats of preliminary, blinded, early, and small data, the MBX 4291 update looks good. We are confident that the PK profile supports monthly dosing, which is a meaningful development. Additionally, the GLP/GIP agonist, which was designed for similar potency as tirzepatide, looks effective, with up to 16% weight loss after just eight weeks. And importantly, the gradual accumulation of drug supports a ‘self-titrating’ dosing paradigm, which translated into a GI tolerability profile

MBX Biosciences (MBX) PT Raised to $86 at Citizens on 'Good' MBX 4291 Update

Tue, 12 May 2026 05:37:52 -0400

Citizens analyst Jonathan Wolleben raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $86.00 (from $76.00) while maintaining a Market Outperform rating.
The analyst commented, "With the caveats of preliminary, blinded, early, and small data, the MBX 4291 update looks good. We are confident that the PK profile supports monthly dosing, which is a meaningful development. Additionally, the GLP/GIP agonist, which was designed for similar potency as tirzepatide, looks effective, with up to 16% weight loss after just eight weeks. And importantly, the gradual accumulation of drug supports a ‘self-titrating’ dosing paradigm, which translated into a GI tolerability profile

MBX Biosciences (MBX) PT Raised to $86 at Citizens on 'Good' MBX 4291 Update

Tue, 12 May 2026 05:37:52 -0400

Citizens analyst Jonathan Wolleben raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $86.00 (from $76.00) while maintaining a Market Outperform rating.
The analyst commented, "With the caveats of preliminary, blinded, early, and small data, the MBX 4291 update looks good. We are confident that the PK profile supports monthly dosing, which is a meaningful development. Additionally, the GLP/GIP agonist, which was designed for similar potency as tirzepatide, looks effective, with up to 16% weight loss after just eight weeks. And importantly, the gradual accumulation of drug supports a ‘self-titrating’ dosing paradigm, which translated into a GI tolerability profile